Please assess the completion status of the following clinical trial:

Trial Title: A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a histologic or cytologic diagnosis of intrahepatic cholangiocarcinoma with stage IV;~* Have progressed after systematic chemotherapy/target therapy, or cannot tolerated with first-line treatment;~* The previous treatment and the present trial registration must be at least 2 weeks apart, and they must have recovered from any toxicity of a previous treatment;~* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1;~* Eastern Cooperative Oncology Group performance score (ECOG): 0-2;~* Life expectancy of at least 12 weeks;~* Subjects who understand and voluntarily signed a written informed consent form.~Exclusion Criteria:~* Previous locoregional therapy within 4 weeks prior to enrollment.~* Diagnosed with hepatocellular carcinoma, mixed cell carcinoma and fibrolamellar hepatocellular carcinoma.~* History of other malignancy within 5 years except for non-melanoma skin cancer, cervix in situ carcinoma.~* Prepared for liver transplantation.~* Patients with contraindications (active bleeding, ulcers, intestinal perforation, intestinal obstruction, within 30 days after major surgery, uncontrolled high blood pressure medication, III-IV level cardiac insufficiency, severe liver and kidney dysfunction).~* A previous history of Interstitial pulmonary disease, drug-induced interstitial disease, radiation pneumonitis requiring hormonal therapy or active interstitial lung disease with any clinical evidence.~* Use of CYP3A4 inhibitor within 7 days or CYP3A4 inducer within 12 days prior to enrollment.~* Patients with central nervous system metastases or brain metastasis~* Previous definite diagnosis of neuropsychiatric disturbances, including epilepsy or dementia.~* Pregnant or lactating women.~* Patients with bone metastasis received palliative radiation within 4 weeks prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apatinib (Type: EXPERIMENTAL): A molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.

Based on this trial design, predict the completion outcome and termination type (if applicable).